Inspired by Sarah

I’d like to share a blog post authored by Sarah Knotts —  a customer who recently switched over to the MiniMed™ 670G system. Sarah was initially skeptical of our hybrid closed-loop system but after trying it, she said the system “gave [her] peace of mind.”

Like many living with Type 1 diabetes (T1D), managing my disease is a part of the way I live my life. I was diagnosed almost 30 years ago, and since then, I’ve been on several insulin pumps from different companies. While they all had their pros and cons, the MiniMed 670G system has been a true game-changer for me.

I started on my MiniMed™ 670G system during the summer of 2017 and within just two weeks, my Time in Range increased 11 percent, which is just remarkable. In addition to the clinical benefits, it’s helped ease so much of the mental burden that I deal with on a daily basis. Because it automatically delivers basal insulin, I can go on with my day knowing the system is taking care of me. For the first time, I feel like it’s not a huge burden to live with diabetes anymore. The constant background noise in my head from thinking about my T1D is gone and I’m just able to be present and live in the moment — whether at work, as a wife, or as a mom. This helps me focus on work and raising a family, which is what currently occupies most of my attention, and is where I want most of my attention to be during the day.

When I firstreceived my MiniMed™ 670G system, I tried to minimize my expectations – after all this was not my first “new” pump. I wanted to be open-minded and see exactly how it would work for me. I took training right before I went out of town on business and was so thankful I did. I’ve always struggled with lows and before going on the MiniMed™ 670G system, I couldn’t seem to get control of them. During the last month on my previous pump, I experienced 11 severe lows — one of which was in the 20’s.

During the first 48 hours on the system, I was in what’s called “Manual Mode” using the SmartGuard™ Suspend Before Low feature. This “warm-up” period allows the system to learn your total daily insulin dose needs. This feature saved me from going low so many times that I was contemplating just staying in this mode and not advancing to “Auto Mode” — the most advanced SmartGuard™ algorithm available in the system. I also wanted to evaluate the performance of the Guardian™ Sensor 3 before trying Auto Mode so I wore a Dexcom sensor in parallel to compare the performance. The accuracy of the Guardian™ Sensor 3 blew me away. I am getting the same accuracy — or better — than I experienced on other CGMs I had used in the past.

This gave me the confidence I personally needed to advance to Auto Mode and I’m so glad I did.This is the true differentiator of the system as it allows the pump to automatically deliver my background (or basal) insulin 24 hours a day, based on my needs, and how my glucose levels are trending. This has been a huge benefit as it takes care of most of my blood sugar fluctuations without me having to even think about it — even when my body is being more insulin resistant or when I am exercising.

Now, I’m staying in my target range roughly 80 percent of the time, and my lows and highs significantly reduced. I’m also able to wake up in range and sleep through the night more often — which sets me up for a better day all around, even in terms of my mood and overall attitude (my husband noticed this right away).

While I began on the MiniMed™ 670G system with limited expectations, I am happy with my progress thus far! The extra help  I get from the system has become integral to my life and today, I can’t imagine living without it. You couldn’t take it away from me if you tried!

I don’t worry the way I used to before, and for the first time in maybe 30 years since my diagnosis, I can relax. Of course, I still have to think about my T1D, but the burden is much less. It’s not a huge thing to live with diabetes now.

Sarah

IMPORTANT SAFETY INFORMATION

The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).

WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products.

Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.

The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.

For complete safety information, please consult the appropriate User Guide.

Print This Post Print This Post
Tags: , , , ,

Post A Comment

Your email address will not be published. Required fields are marked *